stoxline Quote Chart Rank Option Currency Glossary
  
Allakos Inc. (ALLK)
1.17  0.01 (0.86%)    06-17 16:00
Open: 1.15
High: 1.17
Volume: 183,881
  
Pre. Close: 1.16
Low: 1.12
Market Cap: 104(M)
Technical analysis
2024-06-17 5:21:23 PM
Short term     
Mid term     
Targets 6-month :  1.58 1-year :  1.76
Resists First :  1.35 Second :  1.5
Pivot price 1.23
Supports First :  1.1 Second :  0.91
MAs MA(5) :  1.22 MA(20) :  1.27
MA(100) :  1.26 MA(250) :  2.28
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  24.3 D(3) :  34.5
RSI RSI(14): 44.6
52-week High :  5.63 Low :  0.98
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALLK ] has closed above bottom band by 26.5%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.17 - 1.18 1.18 - 1.19
Low: 1.1 - 1.11 1.11 - 1.12
Close: 1.15 - 1.17 1.17 - 1.18
Company Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Headline News

Sun, 09 Jun 2024
Charges Against Allakos Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate - WICZ

Sun, 02 Jun 2024
Allakos (NASDAQ:ALLK) Shares Up 3.3% - Defense World

Fri, 31 May 2024
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know - Yahoo Movies UK

Sat, 03 Feb 2024
Allakos Inc Announces CMO Retirement and Successor - TipRanks.com - TipRanks

Thu, 18 Jan 2024
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks - Yahoo Finance

Tue, 16 Jan 2024
ALLK Stock Quote Price and Forecast - CNN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 89 (M)
Shares Float 59 (M)
Held by Insiders 2.5 (%)
Held by Institutions 93.5 (%)
Shares Short 5,080 (K)
Shares Short P.Month 5,700 (K)
Stock Financials
EPS -2.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.16
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.6 %
Return on Equity (ttm) -111.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.16
Qtrly Earnings Growth 0 %
Operating Cash Flow -119 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio -0.48
PEG Ratio -0.1
Price to Book value 1
Price to Sales 0
Price to Cash Flow -0.88
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android